Navigation Links
Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Date:12/27/2007

a very significant event for patients at the University of Pennsylvania and nationwide who are diagnosed with ovarian cancer. We are excited to work with Northwest Biotherapeutics on this cutting edge clinical trial, and to test the DCVax(R) platform on an additional cancer that carries a poor prognosis."

Dr. Carl June, the Penn sponsor on the trial, stated, "the combination of DCVax(R)-L for ovarian cancer with adoptive immunotherapy using T cells primed by DCVax(R)-L is an innovative approach that deserves testing in clinical trials."

"We are very pleased to add Ovarian cancer to the DCVax(R) platform, and to have Dr. George Coukos and Dr. Carl June lead this effort as the principal investigators for this clinical trial," stated Alton Boynton, President and Chief Executive Officer of Northwest Biotherapeutics. "Drs. Coukos and June are world renowned experts in immunotherapy and in ovarian cancer. They are playing a major role in the pioneering of novel cancer treatment strategies -- particularly by combining multiple different therapeutic approaches."

Ovarian cancer is the fourth leading cause of cancer death among women in the U.S. Approximately 22,400 new cases were diagnosed in the U.S. in 2006, and about 15,300 deaths occurred. In the majority of ovarian cancer cases, the disease has already reached late stage, and spread beyond the ovaries, before it is detected and diagnosed. After initial surgical removal of tumors, and treatment with currently available drugs, the median time to disease recurrence is 18 to 20 months. Recurrent disease is considered incurable and usually results in death, even with aggressive chemotherapy treatments. Accordingly, there is a major unmet medical need for new and more effective treatments for ovarian cancer -- especially recurrent ovarian cancer.

The DCVax(R) platform uses a patient's own tumor, surgically removed as part of the standard of care, to prepare a mix of their personal cancer biomarkers
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Novel Technology Breaks Through Cancer Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
(Date:8/3/2015)... Ill. , Aug. 3, 2015  Landauer, Inc. ... and environmental radiation measurement and monitoring, outsourced medical physics ... it will release financial results for the fiscal third ... 10, 2015. The Company will also ... 11, 2015 at 9:00 a.m. Central Time (10:00 a.m. ...
(Date:8/3/2015)... (Nasdaq: DRRX ) announced today financial results for the ... net loss was $5.5 million for the three months ended ... million and net loss of $5.5 million for the three ... cash and investments of $37.8 million, compared to cash and ... 30, 2015, we had $19.8 million in long term debt. ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10
... deep regret, Adeona Pharmaceuticals, Inc. (Amex: AEN ... President of Research & Development, David A. Newsome, M.D. ... first person to pioneer and demonstrate the benefits of ... the leading cause of blindness in older Americans. Oral ...
... SHENZHEN, China, Feb. 25, 2011 /PRNewswire-Asia/ -- Tongjitang Chinese ... TCM ), announced that it has called an extraordinary ... at 10:00 a.m. (China time) on Thursday, March 31, ... B, Nanshan Medical Device Park, 1019 Nanhai Avenue, Nanshan ...
Cached Medicine Technology:Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development 2Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development 3Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 2Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 3
(Date:8/4/2015)... ... 04, 2015 , ... Oriental Trading Company, Inc., the nation’s ... school supplies, has developed engaging and affordable teacher supplies based on the beloved ... rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant illustrations and inspirational ...
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years of marital ... vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas lead the ... Following the ceremony was a reception, with music by the Moonlight Serenade Orchestra and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Loyola University ... that its RN to BSN and Master of Science in Nursing in ... June 2020 from the Commission on Collegiate Nursing Education (CCNE), the ...
(Date:8/4/2015)... ... 04, 2015 , ... Lightning Labels is pleased to announce ... will usher in a new standard of sticker and label-making for the company. ... its twin objectives of quality and quantity without compromising the signature lightning-fast speed ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... their partnership to make the Isabel Symptom Checker available to all users of ... a mechanism to check their symptoms in an easy, intuitive method, provides access ...
Breaking Medicine News(10 mins):Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3
... FRANKLIN LAKES, N.J., Jan. 16 BD (Becton,Dickinson and ... company,announced today that it will host a live webcast ... 2008, at 1 p.m. (ET)., The webcast can ... and will be available for replay through Tuesday,February ...
... Agreement Provides for Provider Services, Inc. to fund $600,000 for Product, ... Millennium pursuant to the terms of the $20,000,000 5-year Purchase ... ... N.J., Jan. 16 Millennium Biotechnologies,Inc., wholly owned subsidiary of Millennium ...
... STERIS Corporation,(NYSE: STE ) today announced that ... release before the market opens on January 30, ... Eastern time. The conference,call can be heard live ... via phone,by dialing 1-888-392-9976 in the United States ...
... 16 OMI Medical Imaging, Inc. (OMI),announced today that ... with the U.S. Bankruptcy Court for the Southern District ... Reduction Act reimbursement cuts took effect on,January 1, 2007, ... to its secured lenders., OMI operates 21 free ...
... will respond best to interferon beta treatments , WEDNESDAY, ... why some multiple sclerosis (MS) patients respond to treatment ... with 206 southern European patients with relapsing-remitting MS, the ... the DNA of patients whose symptoms were reduced by ...
... The School of Dentistry at LSU Health Sciences Center ... dental institution recipient of the William J. Gies Award ... the ADEAGies Foundation at a black-tie celebration on March ... Education Association (ADEA) Annual Session at the Hilton Anatole ...
Cached Medicine News:Health News:Millennium Enters Into $600,000 Product Development Agreement to Fund Product Development for the $20,000,000 Purchase Agreement with Provider Services, Inc. 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call 2Health News:STERIS Corporation Announces Date of Fiscal 2008 Third Quarter Earnings Release and Conference Call 3Health News:OMI Medical Imaging, Inc. and Affiliated Companies File Chapter 11 Reorganization 2Health News:DNA Analysis Could Help Customize Treatments for MS 2Health News:LSUHSC dental school to be awarded top national honor 2
Fine & Medium Tapers....
Contour Design Eyelid Implants....
For Frontalis Suspension in patients with significant ptosis and poor levator function....
Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be easily drill...
Medicine Products: